UK Device Manufacturers Must Contingency Plan For A Hard Brexit
Executive Summary
The compromise tone adopted last week by the UK government on key "phase 1" issues of an EU-UK Brexit deal was welcomed by UK health-care products industries, but with uncertainty over phase 2 – the future EU trade deal – still hampering UK business planning, local companies have no choice but to begin contingencies for a hard Brexit. Overseas stakeholders are also starting to distance themselves from a UK still unable to commit to a post-2019 relationship with the EU27.
You may also be interested in...
UK Life-Sciences Sector Deal Brings Life And Funding To Industrial Strategy
The next step in the UK government's life-science strategy, the Life Sciences Sector Deal, was issued today, setting out a blueprint of government-support mechanisms and private investment across the whole of the sector. The deal, signaled yesterday at UK HealthTech 2017, seeks to maximize the potential of medtech and pharma businesses, and exploit the value of the NHS.
'Hard' Brexit And Damage To MHRA's EU Medtech Reg Role Causing UK Concern
Few it seems want the UK MHRA to lose its strong input into EU medtech regulatory affairs. But the UK's brinkmanship on a hard Brexit and refusal to countenance any jurisdiction for the European Court of Justice post-Brexit could spell a severely diminished role for the UK health care regulator in EU matters after March 2019.
AI Medical Imaging And Radiotherapy First For UK’s NICE
Inaugural artificial intelligence recommendations from NICE on radiotherapy contouring should allow clinicians to spend more time with patients and on complex cases where AI is not an option. But large language models are not appropriate in all cases, cautions Adrian Sutherland, principal healthcare architect at Endava consultancy.